AI and Drug Discovery: Javier Tordable, CEO and Founder of Pauling AI

About this episode

In the AI Risk Reward podcast, our host, Alec Crawford (@alec06830), Founder and CEO of Artificial Intelligence Risk, Inc. aicrisk.com , interviews guests about balancing the risk and reward of Artificial Intelligence for you, your business, and society as a whole. Podcast production and sound engineering by Troutman Street Audio. You can find them on LinkedIn.

In this episode, Alec speaks with Javier Tordable, CEO and Founder of Pauling AI, about the transformative potential of AI in drug discovery. Javier shares his journey from mathematics and technology roles at Microsoft and Google to launching Pauling AI, highlighting the importance of innovation and mentorship in shaping his career. He explains how Pauling AI aims to automate the process of moving from scientific hypothesis to molecule testing, thereby accelerating and reducing the cost of bringing new medicines to market. The discussion covers the ethical considerations of AI in life sciences, the realistic risks of misuse, and the challenges posed by today’s advanced content generation capabilities. Javier also provides practical advice for pharma CEOs considering AI adoption and reflects on the evolving role of regulators in healthcare and technology.

Summary:

1. AI for Drug Discovery: Javier Tordable outlines how Pauling AI leverages automation and language models to speed up the process of identifying and testing new therapeutics.
2. Career and Mentorship: Javier’s background in mathematics, technology, and leadership at Google informs his approach to building impactful AI solutions in life sciences.
3. Ethical Considerations: The episode addresses the dual-use nature of AI in science, noting both its potential for positive impact and the manageable risks of misuse.
4. Industry Disruption: Javier advises traditional pharma leaders to partner with AI experts rather than attempt to independently build state-of-the-art capabilities.
5. Regulatory Perspective: The conversation highlights the complexity regulators face and suggests global best practices, particularly with reference to the U.S. FDA and China’s accelerated clinical trial environment.

Companies/Organizations:

1. Pauling AI
2. Artificial Intelligence Risk, Inc.
3. Google
4. Microsoft
5. Nintendo
6. Meditech
7. Schrodinger
8. Future House
9. Edison Scientific
10. OpenAI
11. FDA
12. Netflix
13. Warner Brothers
14. Amazon
15. Apple

Books:

1. Isaac Asimov’s Foundation series

Movies:

1. The Matrix Reloaded

TV Shows:

1. Foundation

Copyright © 2025 by Artificial Intelligence Risk, Inc.